Sorry but this tells me a couple of things:
1. currently OC is being diagnosed and surgery performed by non-OCs - WTF? Why would they be allowed to do this and why would patients not consult OCs? How would insurers cover any assessment or surgery by non-OCs? What am I missing?
2. The current assessment is using unapproved methods or their assessment is ineffective - this is the market Cleo is targeting. Whether the blood test is either ordered by an OC or not, if the blood test is the one Cleo has identified as having higher sensitivity and specificity, then the doctors have better data to base their decisions on.
Please let me know what I may have missed. Ta
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark, page-63
Add COV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $26.11M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.0¢ | $70.84K | 222.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 29329 | 2 |
View Market Depth
| Last trade - 15.00pm 22/07/2024 (20 minute delay) ? |
| COV (ASX) Chart |